see page 17
The determination of primary efficacy was based on a planned
interim analysis of 762 subjects. At the interim analysis, 7.3% of patients who received LAGEVRIO were either hospitalized or died through Day 29 (28/385), compared with 14.1% of placebo-treated patients (53/377). The adjusted risk difference was -6.8% with a 95% CI of (-11.3%, -2.4%) and 2-sided p-value = 0.0024
Seems somewhat efficacious. Looks to still be under EUA. I would be hesitant to take this experimental drug.
This drug has more safety and efficacy data in humans...https://c19ivm.org/meta.html
Thanks so much this is the information I needed for her.